Stocks
Amgen Financial Statements (AMGN) |
||||||||||
| Amgensmart-lab.ru | % | 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2023Q4 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 28.04.2023 | 04.08.2023 | 31.10.2023 | 06.02.2024 | 14.02.2024 | 14.02.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 6 105 | 6 986 | 6 903 | 8 196 | 8 196 | 30 281 | |||
| Operating Income, bln rub | 3 085 | 2 684 | 2 021 | 1 271 | 1 271 | 7 247 | ||||
| EBITDA, bln rub | ? | 3 985 | 2 366 | 2 706 | 1 271 | 3 053 | 9 396 | |||
| Net profit, bln rub | ? | 2 841 | 1 379 | 1 730 | 767.0 | 767.0 | 4 643 | |||
| OCF, bln rub | ? | 1 064 | 4 109 | 2 760 | 538.0 | 538.0 | 7 945 | |||
| CAPEX, bln rub | ? | 344.0 | 271.0 | 248.0 | 249.0 | 249.0 | 1 017 | |||
| FCF, bln rub | ? | 720.0 | 3 838 | 2 512 | 289.0 | 289.0 | 6 928 | |||
| Dividend payout, bln rub | 1 137 | 1 139 | 1 140 | 0.000 | 1 140 | 3 419 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 40.0% | 82.6% | 65.9% | 0.00% | 148.6% | 73.6% | ||||
| OPEX, bln rub | 2 464 | 2 489 | 3 076 | 3 813 | 3 813 | 13 191 | ||||
| Cost of production, bln rub | 1 720 | 1 813 | 1 806 | 3 112 | 3 112 | 9 843 | ||||
| R&D, bln rub | 1 058 | 1 113 | 1 079 | 1 534 | 1 534 | 5 260 | ||||
| Interest expenses, bln rub | 543.0 | 752.0 | 759.0 | 821.0 | 821.0 | 3 153 | ||||
| Assets, bln rub | 88 720 | 90 269 | 90 534 | 97 154 | 97 154 | 97 154 | ||||
| Net Assets, bln rub | ? | 5 348 | 6 781 | 7 656 | 6 232 | 6 232 | 6 232 | |||
| Debt, bln rub | 61 595 | 61 544 | 60 468 | 64 613 | 64 613 | 64 613 | ||||
| Cash, bln rub | 31 561 | 34 248 | 34 741 | 10 944 | 10 944 | 10 944 | ||||
| Net debt, bln rub | 30 034 | 27 296 | 25 727 | 53 669 | 53 669 | 53 669 | ||||
| Ordinary share price, rub | 241.8 | 222.0 | 268.8 | 288.0 | 288.0 | 268.0 | ||||
| Number of ordinary shares, mln | 534.0 | 535.0 | 535.0 | 535.0 | 535.0 | 535.0 | ||||
| Market cap, bln rub | 129 095 | 118 781 | 143 787 | 154 091 | 154 091 | 143 391 | ||||
| EV, bln rub | ? | 159 129 | 146 077 | 169 514 | 207 760 | 207 760 | 197 060 | |||
| Book value, bln rub | -25 576 | -23 383 | -21 003 | -45 038 | -45 038 | -45 038 | ||||
| EPS, rub | ? | 5.32 | 2.58 | 3.23 | 1.43 | 1.43 | 8.68 | |||
| FCF/share, rub | 1.35 | 7.17 | 4.70 | 0.54 | 0.54 | 12.9 | ||||
| BV/share, rub | -47.9 | -43.7 | -39.3 | -84.2 | -84.2 | -84.2 | ||||
| EBITDA margin, % | ? | 65.3% | 33.9% | 39.2% | 15.5% | 37.2% | 31.0% | |||
| Net margin, % | ? | 46.5% | 19.7% | 25.1% | 9.36% | 9.36% | 15.3% | |||
| FCF yield, % | ? | 5.83% | 8.15% | 6.52% | 4.94% | 4.78% | 4.83% | |||
| ROE, % | ? | 148.0% | 117.7% | 98.8% | 107.8% | 107.8% | 74.5% | |||
| ROA, % | ? | 8.92% | 8.84% | 8.36% | 6.91% | 6.91% | 4.78% | |||
| P/E | ? | 16.3 | 14.9 | 19.0 | 22.9 | 22.9 | 30.9 | |||
| P/FCF | 17.1 | 12.3 | 15.3 | 533.2 | 20.9 | 20.7 | ||||
| P/S | ? | 4.93 | 4.47 | 5.36 | 5.47 | 5.47 | 4.74 | |||
| P/BV | ? | -5.05 | -5.08 | -6.85 | -3.42 | -3.42 | -3.18 | |||
| EV/EBITDA | ? | 14.8 | 13.0 | 15.1 | 20.1 | 17.2 | 21.0 | |||
| Debt/EBITDA | 2.79 | 2.42 | 2.29 | 5.20 | 4.43 | 5.71 | ||||
| R&D/CAPEX, % | 307.6% | 410.7% | 435.1% | 616.1% | 616.1% | 517.2% | ||||
| CAPEX/Revenue, % | 5.63% | 3.88% | 3.59% | 3.04% | 3.04% | 3.36% | ||||
| Amgen shareholders | ||||||||||
